drugset / Trial / NCT04198480
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
Phase 1/2
Terminated
4 enrolled
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.
Timeline
- Start
- 2020-04-22
- Primary completion
- 2021-10-25
- Completion
- 2021-10-25
Outcome
Outcome not reported
Stopped (Business): “Due to a change in the company's research strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JMT103 | Monoclonal antibody | 2 mg/kg | Subcutaneous |